beeldscherm schreef op 8 maart 2019 12:30:
LFB STRATEGIC TRANSFORMATION PROJECT
Les Ulis (France), 6 February 2019 – LFB unveils its strategic transformation project
Denis Delval, LFB Chairman and CEO, stated “our strategic transformation project is crucial for our future. It is underpinned by refocusing on our core business and creating added value for patient care. We have four main priorities. Our first priority is on our industrial activity to support market growth. The second is to refocus on our core businesses, the medicinal products derived from plasma or recombinant proteins used in immunology, haematology and emergency medicine. Our third priority is consolidating LFB’s position in France and targeted international growth. And finally, refocusing our core business operations means we need a new organisation.
..
Refocusing on core business activities, plasma derived or recombinant therapeutic proteins
LFB has taken a strategic decision to refocus on its core business – production and provision of its 15 plasma or recombinant protein derived products used in immunology, haematology and emergency medicine.
zeer int.
www.groupe-lfb.com/en/news/lfb-strate...